跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 16 天前AI 评分49

勃林格殷格翰与中国信诺生物医药达成70亿美元癌症药物开发协议

Boehringer Ingelheim strikes $7B backloaded ADC, TCE cancer deal with China's Sino

AI 导读

德国勃林格殷格翰与中国信诺生物医药达成70亿美元的合作协议,专注于癌症药物开发。

正文

Ger­many’s Boehringer In­gel­heim is fur­ther plant­i­ng its stake in Chi­na, team­ing up with Sino Bio­phar­ma­ceu­ti­cal in a can­cer drug de­vel­op­ment deal that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news